Skip to content
Adrienne Monson – Lifestyle
Author:
Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 3, 2026
Milestone Pharmaceuticals to Announce Third Quarter 2026 Financial Results on November 13, 2026
November 3, 2026
New Data Presented at AHA Scientific Sessions 2026 Demonstrate That CARDAMYST® (etripamil) Nasal Spray Converted Recurrent PSVT to Normal Heart Rhythm in Patients with Prior Catheter Ablation
November 2, 2026
Milestone Pharmaceuticals Announces Clinical Data Presentations at Upcoming Cardiology Conferences
October 19, 2026
Milestone Pharmaceuticals Announces First European Study Participant Enrolled in ReVeRA-301 Phase 3 Clinical Trial
October 13, 2026
Milestone Pharmaceuticals Enrolls First Canadian Study Participant in ReVeRA-301 Phase 3 Pivotal Trial Evaluating Etripamil Nasal Spray for AFib-RVR
September 24, 2026
Milestone Pharmaceuticals Announces NMPA Approval of Etripamil Nasal Spray for PSVT in China, Marking First Regulatory Approval of Etripamil Outside of the United States
September 3, 2026
Milestone Pharmaceuticals to Present at Upcoming Investor Conferences
September 2, 2026
Milestone Pharmaceuticals Announces Data Presented at ESC Congress 2026 on the Impact of Paroxysmal Supraventricular Tachycardia (PSVT) on Patients’ Daily Lives and Quality of Life Between Episodes
August 27, 2026
Milestone Pharmaceuticals Initiates Pivotal Phase 3 Trial of Etripamil Nasal Spray for Self-Administered Treatment of Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR)
August 21, 2026
1
2
Next Page
→